These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37005335)

  • 1. Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations.
    Martins FS; Martins JES; Severino P; Annaert P; Sy SKB
    Br J Clin Pharmacol; 2023 Sep; 89(9):2726-2738. PubMed ID: 37005335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the in vivo efficacy of ceftaroline fosamil, vancomycin and daptomycin in a murine model of methicillin-resistant Staphylococcus aureus bacteraemia.
    García P; Moscoso M; Fernández MC; Fuentes-Valverde V; Pérez A; Bou G
    Int J Antimicrob Agents; 2023 Jul; 62(1):106836. PubMed ID: 37150362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Werth BJ; Barber KE; Ireland CE; Rybak MJ
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing probability of target attainment against Staphylococcus aureus for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models.
    Cristinacce A; Wright JG; Macpherson M; Iaconis J; Das S
    Diagn Microbiol Infect Dis; 2021 Apr; 99(4):115292. PubMed ID: 33360809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study.
    Arshad S; Huang V; Hartman P; Perri MB; Moreno D; Zervos MJ
    Int J Infect Dis; 2017 Apr; 57():27-31. PubMed ID: 28131729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections.
    Das S; Li J; Iaconis J; Zhou D; Stone GG; Yan JL; Melnick D
    J Antimicrob Chemother; 2019 Feb; 74(2):425-431. PubMed ID: 30380060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.
    da Costa TM; Cuba GT; Morgado PGM; Nicolau DP; Nouér SA; Dos Santos KRN; Kiffer CRV
    BMC Infect Dis; 2020 Jan; 20(1):74. PubMed ID: 31973753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed M; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3522-6. PubMed ID: 21576449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care.
    Johnson TM; Molina KC; Miller MA; Kiser TH; Huang M; Mueller SW
    Int J Antimicrob Agents; 2021 Apr; 57(4):106310. PubMed ID: 33609718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline.
    Sakoulas G; Moise PA; Casapao AM; Nonejuie P; Olson J; Okumura CY; Rybak MJ; Kullar R; Dhand A; Rose WE; Goff DA; Bressler AM; Lee Y; Pogliano J; Johns S; Kaatz GW; Ebright JR; Nizet V
    Clin Ther; 2014 Oct; 36(10):1317-33. PubMed ID: 25017183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.
    Geriak M; Haddad F; Rizvi K; Rose W; Kullar R; LaPlante K; Yu M; Vasina L; Ouellette K; Zervos M; Nizet V; Sakoulas G
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli.
    Morrisette T; Lagnf AM; Alosaimy S; Rybak MJ
    Eur J Clin Microbiol Infect Dis; 2020 Nov; 39(11):2199-2203. PubMed ID: 32535805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Daptomycin Plus Ceftaroline Versus Alternative Therapy for Persistent Methicillin-resistant Staphylococcus aureus (MRSA) Bacteraemia.
    Patel D; Brown ML; Edwards S; Oster RA; Stripling J
    Int J Antimicrob Agents; 2023 Mar; 61(3):106735. PubMed ID: 36690124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy.
    Ho TT; Cadena J; Childs LM; Gonzalez-Velez M; Lewis JS
    J Antimicrob Chemother; 2012 May; 67(5):1267-70. PubMed ID: 22311935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
    Bhalodi AA; Hagihara M; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2014; 58(2):672-7. PubMed ID: 24217694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacteremia due to Methicillin-Resistant Staphylococcus aureus: New Therapeutic Approaches.
    Holubar M; Meng L; Deresinski S
    Infect Dis Clin North Am; 2016 Jun; 30(2):491-507. PubMed ID: 27208769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity.
    Rose WE; Schulz LT; Andes D; Striker R; Berti AD; Hutson PR; Shukla SK
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5296-302. PubMed ID: 22869564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations.
    Paladino JA; Jacobs DM; Shields RK; Taylor J; Bader J; Adelman MH; Wilton GJ; Crane JK; Schentag JJ
    Int J Antimicrob Agents; 2014 Dec; 44(6):557-63. PubMed ID: 25282169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.
    Riccobene TA; Khariton T; Knebel W; Das S; Li J; Jandourek A; Carrothers TJ; Bradley JS
    J Clin Pharmacol; 2017 Mar; 57(3):345-355. PubMed ID: 27510635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
    Zasowski EJ; Trinh TD; Claeys KC; Casapao AM; Sabagha N; Lagnf AM; Klinker KP; Davis SL; Rybak MJ
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.